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Hypertension makes a major contribution to the global burden of
cardiovascular disease, particularly myocardial infarction and
stroke.1,2 It is increasingly recognised as a treatable risk factor
for disorders affecting the brain, including dementia and late-life
depression.3,4 Hypertension leads to cerebral small vessel disease5
and may reduce white matter integrity in frontostriatal regions6
and is therefore hypothesised to contribute to the structural brain
changes found in cognitive impairment and late-life depression.7
To date, however, few studies have examined the association
between hypertension and brain structure using magnetic resonance
imaging (MRI) in non-clinical populations. Previous studies suggest
that older people with hypertension may have smaller whole brain
volumes compared with normotensive individuals,8 and possibly
an increased rate of whole brain atrophy.9 Participants with
untreated hypertension may also have an increased risk for
hippocampal atrophy,10,11 although this is not a universal
observation.8,12 Hypertension is associated with age-related white
matter changes,13,14 increased white matter lesion load and
volume9,15–17 and reduced white matter integrity.18–21 However,
these associations continue to be debated because of several
shortcomings in the evidence: many studies are based on cross-
sectional data14,17,18 or have short follow-ups;11,22 use small
samples20 or younger participants with, because of their age,
limited exposure to the effects of hypertension;18,19 ignore the
potential effects of antihypertensive drug treatment;8,15,17 use
low-resolution MRI15 without a fully automated MRI analysis
technique10 or focus only on white matter.13 Furthermore,
although dose–response patterns provide support for a causal
association, few studies have examined whether a longer exposure
to hypertension is associated with greater changes in brain
structure. In this study, we combined longitudinal data on blood
pressure and hypertension from across the adult life course with
high-resolution MRI at older ages to investigate the effects of
hypertension, and treatment of hypertension, on brain structure.
We hypothesised there would be an association between current
blood pressure and brain structure, with greater structural changes
in those with more severe forms of hypertension. When considering
longitudinal data, we hypothesised that those with a longer history
of hypertension would be more likely to show structural brain
abnormalities in late life, particularly within white matter.
Method
Participants
Men and women from the Whitehall II study23 participated in a
structured clinical interview, brief clinical examination (including
blood pressure measurement) and an MRI scan in Oxford
between April 2012 and March 2013 as part of the Whitehall
Imaging substudy. Consenting participants from phases 10 and
11 of the Whitehall II study were randomly selected to participate.
Ethical approval for this study was provided through the Oxford
NHS Research Ethics Committee (Reference: 10/H0606/71) and
Central University Research Ethics Committee (Reference: MSD/
IDREC/C1/2011/71). Previous clinical examinations for these
participants, including the measurement of blood pressure, were
undertaken in 1985–1988, 1991–1993, 1997–1999, 2003–2005,
and 2008–2009 through the Whitehall II Study, London.
Assessment of blood pressure and hypertension
Blood pressure was measured in 1985–1988, 1991–1993, 1997–1999,
2003–2005, and 2008–2009 as part of the Whitehall II study and in
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Hypertension is associated with an increased risk of
dementia and depression with uncertain longitudinal
associations with brain structure.
Aims
To examine lifetime blood pressure as a predictor of brain
structure in old age.
Method
A total of 190 participants (mean age 69.3 years) from the
Whitehall II study were screened for hypertension six times
(1985–2013). In 2012–2013, participants had a 3T-magnetic
resonance imaging (MRI) brain scan. Data from the MRI were
analysed using automated and visual measures of global
atrophy, hippocampal atrophy and white matter
hyperintensities.
Results
Longitudinally, higher mean arterial pressure predicted
increased automated white matter hyperintensities
(P50.002). Cross-sectionally, hypertensive participants
had increased automated white matter hyperintensities
and visually rated deep white matter hyperintensities. There
was no significant association with global or hippocampal
atrophy.
Conclusions
Long-term exposure to high blood pressure predicts
hyperintensities, particularly in deep white matter. The
greatest changes are seen in those with severe forms of
hypertension, suggesting a dose–response pattern.
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2012–2013 before the MRI scan (the Whitehall Imaging substudy).
Systolic and diastolic blood pressure was measured twice in the
sitting position after 5min of rest with the Hawksley random-0
sphygmomanometer (1985–1988, 1991–1993, 1997–1999) and
OMRON HEM 907 (2003–2005, 2008–2009, 2012–2013).24 The
average of each of the systolic and diastolic blood pressure
readings was used in the analysis. Hypertension was defined
according to the seventh report of the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure: systolic/diastolic 5140/90 mm Hg or use of
antihypertensive medication.25 Based on the 2012—2013 clinic
examination, we divided participants into four groups: normo-
tensive (systolic/diastolic blood pressure 5140/90mmHg and
no treatment), controlled hypertension (blood pressure 5140/
90mmHg and on antihypertensive treatment), untreated hyper-
tension (blood pressure 5140/90mmHg and no treatment) and
poorly controlled hypertension (blood pressure 5140/90mmHg
in spite of treatment). When considering cross-sectional and
longitudinal associations we used ‘mean arterial pressure’ (MAP),
which combines systolic and diastolic blood pressures into a single,
composite measure using the formula: MAP= ((26mean diastolic
pressure)+mean systolic blood pressure))/3.
MRI acquisition and processing
Multimodal MRI scans were acquired at the Oxford Centre for
Functional MRI of the Brain (FMRIB Centre) using a 3-Tesla,
Siemens Magnetom Verio scanner with a 32-channel head coil.
Structural images were acquired using a high-resolution three-
dimensional T1-weighted sequence: repetition time (TR)= 2530ms,
echo time (TE)=7.37ms, flip angle 78, field of view (FOV)=
256mm and voxel dimensions 1.0mm isotropic. T2-weighted fluid
attenuated inversion recovery (FLAIR) images, used to characterise
white matter changes were acquired with: TR= 9000ms,
TE=73.0ms, flip angle 1508, FOV=220mm and voxel dimensions
0.960.963.0mm. MRI data processing and analysis used FSL
tools (FMRIB Software library, www.fmrib.ox.ac.uk/fsl).26–28
Structural, T1-weighted images were processed using fsl_anat
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/fsl_anat). In brief, this included
bias-field correction and brain extraction based on the transform-
ation of a standard-space mask to the input image using non-
linear registration. Tissues were automatically segmented using
FAST.29
MRI analysis
Data from MRI were analysed using visual and automated
techniques to quantify global atrophy, hippocampal atrophy and
white matter hyperintensities.
Visual ratings
Visual assessments of axial and coronal T1-weighted images were
used to quantify global atrophy using a four-point ordinal scale
based on a previous rating (See online Tables DS1–3).30,31 Coronal
T1-weighted images were used to quantify hippocampal atrophy
using the Scheltens’ scale, a five-point ordinal scale (left and right
rated separately).32 T2-weighted FLAIR images were used to assess
white matter hyperintensities using the Fazekas scale.33 White
matter hyperintensities are found throughout the brain, and
appear as brighter lesions on FLAIR images, which represent
neuropathological changes including small and large vessel
vascular pathology, demyelination and gliosis; they are more
common with age, and are associated with cerebrovascular disease,
depression and dementia.34 The Fazekas scale is a seven-point
ordinal scale rated, representing the sum of separate ratings for
periventricular and deep white matter hyperintensities. A higher
score on each of these measures (i.e. global atrophy, hippocampal
atrophy and white matter hyperintensities) indicates greater
structural brain change. Visual ratings were scored independently
by three psychiatrists with substantial interrater (intraclass
correlation (ICC) = 0.63–0.72) and intrarater reliability for all
visual measures (ICC= 0.61–0.75).
Automated ratings
Automated assessment of global atrophy was calculated by
measuring cerebrospinal fluid volumes after partial volume
segmentation using FAST,35 and normalising this value to whole
brain volume. Automated assessment of left and right medial
temporal lobe atrophy utilised FIRST to segment subcortical
structures,29 again normalising hippocampal volumes to whole
brain volume. Automated assessment of total white matter
hyperintensity volume used Freesurfer version 5.1.0 (http://
surfer.nmr.mgh.harvard.edu/). This value was normalised for total
white matter volume. For automated ratings, greater structural
brain change is indicated by higher scores for global atrophy
and white matter hyperintensity volume, and lower scores for
hippocampal volumes.
Statistical analysis
We used SAS software version 9.2 for Windows for all statistical
analyses. In all analyses, reported P-values are 2-tailed; P-values
40.05 were considered to indicate statistical significance. The
age- and gender-adjusted mean levels of blood pressure by hyper-
tension status in 2012–2013 were categorised as: normotension,
controlled hypertension, untreated hypertension and poorly
controlled hypertension. For each of these groups we calculated
mean blood pressures averaged over all measurements taken
between 1985 and 2009, and calculated the percentage of
participants who were hypertensive and were on antihypertensive
treatment at each of the previous measurement times.
To examine cross-sectional associations we computed separate
models for associations of hypertension status with each visual
and automated MRI variable as the dependent variable, adjusted
for age and gender. Visual MRI measures were dichotomised
before analysis (scores 0–1 v. 2–3 for global brain atrophy; scores
0–1 v. 2–4 for left and right hippocampal atrophy; scores 0–1 v.
2–3 for deep and periventricular white matter hyperintensities;
scores 0–2 v. 3–6 for total white matter hyperintensities) and
analysed using logistic regression. For significant results we made
additional adjustment for MAP. We logarithmically transformed
automated measures of white matter hyperintensities to normalise
their skewed distribution. Automated MRI measures were
analysed using analysis of variance.
To study longitudinal associations we computed MAP based
on repeat measurements of blood pressure across five clinical
examinations between 1985 and 2009. The average of these five
phases was combined to form a single measure of MAP. We
included this variable in regression models as a continuous
variable with visual and automated MRI variables as outcomes,
adjusting for age and gender. In analysis of visual MRI measures,
we used logistic regression as described above; automated
measures were analysed using analysis of variance.
Results
In total, 229 participants were recruited to the Whitehall Imaging
substudy between 1 April 2012 and 30 June 2013, with 190 suitable
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for inclusion in this study. Participants were excluded because of
neurological conditions (n= 25), incomplete MRI data (n= 7)
and inadequate MRI processing or grey matter segmentation
(n= 7). The mean age of the sample was 69.3 years (s.d. = 5.4,
range 60–81) and most participants were men (82%). Further
clinical characteristics are presented in Table 1. At the 2012–
2013 MRI scan, 59 (31.1%) participants were normotensive, 30
(15.8%) had controlled hypertension (i.e. normal blood pressure
and on treatment for hypertension), 61 (32.1%) had untreated
hypertension and 40 (21.1%) had poorly controlled hypertension
(i.e. hypertension despite antihypertensive drug treatment).
Table 2 shows that mean systolic and diastolic pressures were
lowest in the normotensive group, and highest in the group with
poorly controlled hypertension and those with untreated or
controlled hypertension between these two groups. This pattern
was replicated when considering mean blood pressures using
measurements taken 1985–2009.
When considering longitudinal history, data show that
differences in blood pressure between the groups identified in
2012–2013 have developed over the previous 28 years (Table 2).
For example, the group with poorly controlled hypertension in
2012–2013 showed a gradual increase in hypertension and use
of antihypertensive medication from 1985 onwards, with over half
of participants already on treatment by 2003–2004, in marked
contrast to other groups.
Table 3 shows that cross-sectionally, there was an association
between blood pressure and MRI brain measures, indicating that
hypertension status is associated with visual and automated MRI
ratings. Using visual measures, after adjustment for age and
gender, participants with controlled hypertension (odds ratio
(OR) = 3.8, 95% CI 1.3–11.1), untreated hypertension (OR= 3.7,
95% CI 1.5–9.0) and poorly controlled hypertension (OR= 4.4,
95% CI 1.6–11.9) had more deep white matter hyperintensities
than the normotensive group (w2 = 11.0, (d.f.) = 3, P for hetero-
geneity 0.01) (Fig. 1). When the association between hypertension
and deep white matter hyperintensities was additionally adjusted
for history of past blood pressure (MAP between 1985 and
2009), participants with controlled hypertension (OR= 4.6, 95%
CI 1.4–15.3), untreated hypertension (OR= 4.2, 95% CI 1.6–
10.9) and poorly controlled hypertension (OR= 5.4, 95% CI
1.7–17.5) still had more deep white matter hyperintensities than
the normotensive group (w2 = 10.1, d.f. = 3, P for heterogeneity
0.02). There was no association with visual measures of peri-
ventricular hyperintensities, but visual measures of total white
matter hyperintensity volume were significant for controlled
(OR= 2.5, 95% CI 1.0–6.4) and poorly controlled groups
(OR= 3.6, 95% CI 1.4–8.9) when compared with the normo-
tensive group. There were no significant trends for whole brain
volume or left hippocampal volume, but right hippocampal
volume was lower in the group with poorly controlled hyper-
tension when compared with the normotensive group (OR= 3.1,
95% CI 1.0–9.1).
Cross-sectional, automated measures showed that participants
with controlled, untreated and poorly controlled hypertension had
significantly increased white matter hyperintensities, which were
0.4 (s.e = 0.2, P= 0.009), 0.4 (s.e. = 0.1, P= 0.002) and 0.5
(s.e. = 0.1, P= 0.0005) standard-deviation units higher compared
with the normotensive group, after adjustment for age and gender
(F= 5.4, d.f. = 3, P= 0.001). Whole brain volume and left and right
hippocampal volume were lower in hypertensive participants,
but these associations did not reach statistical significance at
conventional levels.
Table 4 shows that longitudinally, between 1985 and 2009,
there was an association between MAP and MRI measures, with
higher MAP being associated with both visual and automated
ratings. Using visual ratings, higher MAP was associated
with greater right-hippocampal atrophy (OR= 1.7, 95% CI 1.0–
2.8, w2 = 4.6, d.f. = 1, P= 0.03), which taken together with
cross-sectional data gives an indication of an association, even
though this was not replicated using automated measures.
Using automated ratings, higher MAP was associated with
increased white matter hyperintensities (b= 0.2, s.e. = 0.06,
F= 9.9, d.f. = 1, P = 0.002). This is illustrated in Fig. 2, which
demonstrates that increased MAP measured prospectively over
two decades is associated with increased white matter hyperintensity
volume.
310
Table 1 Characteristics of the study sample at the magnetic
resonance imaging (MRI) examination (n = 190)
Characteristic
Clinical characteristics
Gender, n (%)
Men 155 (81.6)
Women 35 (18.4)
Age, years: mean (s.d.) 69.3 (5.4)
Center for Epidemiologic Studies Depression Scale36
score, mean (s.d.)
6.1 (7.2)
Body mass index, kg/m2: mean (s.d.) 24.4 (3.3)
Years of education, mean (s.d.) 14.1 (3.2)
Hypertension status, n (%)
Normotensive 59 (31.1)
Controlled hypertension 30 (15.8)
Untreated hypertension 61 (32.1)
Poorly controlled hypertension 40 (21.1)
Visual MRI ratings
Global atrophy, n (%)
0 (absent) 4 (2.11)
1 (mild) 84 (44.2)
2 (moderate) 86 (45.3)
3 (severe) 16 (8.4)
Left hippocampal atrophy, n (%)
0 (normal) 56 (29.5)
1 (slight increase) 88 (46.3)
2 (moderate increase) 44 (23.2)
3 (severe increase) 2 (1.05)
Right hippocampal atrophy, n (%)
0 (normal) 54 (28.4)
1 (slight increase) 97 (51.1)
2 (moderate increase) 37 (19.5)
3 (severe increase) 2 (1.05)
Deep white matter hyperintensities (DWM), n (%)a
0 (absent) 3 (1.59)
1 (punctuate foci) 116 (61.4)
2 (beginning confluence of foci) 60 (31.8)
3 (large confluent areas) 10 (5.3)
Periventricular white matter hyperintensities (PVH), n (%)a
0 (absent) 0 (0.0)
1 (caps or pencil thin lining) 106 (56.1)
2 (smooth halo) 72 (38.1)
3 (irregular PVH extending to the deep white matter) 11 (5.8)
White matter hyperintensities
(sum of DWM and PVH scores), n (%)a
0 0 (0.0)
1 3 (1.6)
2 83 (43.9)
3 52 (27.5)
4 35 (18.5)
5 12 (6.3)
6 4 (2.1)
Automated MRI measures, mean (s.d.)
Whole brain volume,10,000 mm3 144.1 (12.8)
Left hippocampal volume, mm3 2369.0 (366.8)
Right hippocampal volume, mm3 2435.8 (317.8)
White matter hyperintensities (Freesurfer), mm3 4944.3 (5916.8)
a. n=189.
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Table 2 A 28-year blood pressure and treatment history by status of hypertension at magnetic resonance imaging (MRI) scan
in 2012–2013
Status in 2012–2013
n
Normotensive
(n=59)
Controlled hypertension
(n=30)
Untreated hypertension
(n=61)
Poorly controlled
hypertension (n=40)
Blood pressure 2012–2013,a mean (s.e.)
Systolic BP 190 126.3 (1.4) 128.9 (1.9) 152.6 (1.3) 156.5 (1.4)
Diastolic BP 190 70.7 (1.1) 72.3 (1.5) 82.4 (1.1) 84.0 (1.4)
Blood pressure 1985–2009,a,b mean (s.e.)
Systolic blood pressure 184 112.9 (1.2) 126.2 (1.6) 122.1 (1.1) 128.2 (1.5)
Diastolic blood pressure 184 69.4 (0.8) 78.7 (1.1) 74.7 (0.8) 78.9 (1.0)
Mean arterial pressure 184 83.9 (0.9) 94.5 (1.2) 90.5 (0.8) 95.3 (1.1)
Hypertension,c % (n)
1985–1988 190 2 (1) 27 (8) 8 (5) 30 (12)
1991–1993 185 0 (0) 17 (5) 15 (9) 35 (14)
1998–1999 185 2 (1) 40 (12) 3 (2) 45 (18)
2003–2004 184 2 (1) 53 (16) 10 (6) 70 (28)
2008–2009 186 0 (0) 93 (28) 12 (7) 98 (39)
2012–2013 190 0 (0) 100 (30) 100 (61) 100 (40)
Antihypertensive treatment,c % (n)
1985–1988 157 0 (0) 13 (4) 0 (0) 3 (1)
1991–1993 125 0 (0) 0 (0) 0 (0) 13 (5)
1998–1999 184 0 (0) 10 (3) 0 (0) 30 (12)
2003–2004 183 0 (0) 30 (9) 0 (0) 53 (21)
2008–2009 185 0 (0) 90 (27) 0 (0) 75 (30)
2012–2013 177 0 (0) 100 (30) 0 (0) 100 (40)
a. Adjusted for age and gender.
b. Mean blood pressure for each participant is the average taking into account all previous measurements.
c. Unadjusted prevalence.
Table 3 Cross-sectional association between blood pressure and magnetic resonance imaging (MRI) brain measures
Visual measuresa Automated measuresa
ORb (95% CI) P b-value (s.e.) P
Global atrophy
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
0.8 (0.3–2.0)
1.4 (0.7–3.0)
1.0 (0.4–2.4)
0.6
0.4
0.9
0.0 (reference)
741027.6 (24635.2)
722930.0 (20052.8)
729300.7 (23651.9)
0.1
0.3
0.2
Left hippocampus
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
1.3 (0.4–4.3)
1.2 (0.5–3.3)
2.2 (0.8–6.3)
0.6
0.7
0.1
0.0 (reference)
70.010 (0.008)
70.007 (0.006)
70.003 (0.007)
0.2
0.3
0.7
Right hippocampus
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
1.4 (0.4–5.0)
1.0 (0.3–3.1)
3.1 (1.0–9.1)
0.6
1.0
0.04
0.0 (reference)
0.0003 (0.007)
70.005 (0.006)
70.006 (0.007)
1.0
0.4
0.4
White matter, deep
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
3.8 (1.3–11.1)
3.7 (1.5–9.0)
4.4 (1.6 –11.9)
0.01
0.005
0.004
N/A N/A
White matter, periventricular
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
2.1 (0.8–5.3)
1.6 (0.7–3.4)
2.2 (0.9–5.3)
0.1
0.2
0.08
N/A N/A
White matter, Fazekas/total
Normotensive
Controlled
Untreated
Poorly controlled
1.0 (reference)
2.5 (1.0–6.4)
2.0 (0.9–4.1)
3.6 (1.4–8.9)
0.05
0.07
0.007
0.0 (reference)
0.4 (0.2)
0.4 (0.1)
0.5 (0.1)
0.009
0.002
0.0005
a. Adjusted for age and gender.
b. Odds ratios associated with a 10mmHg increment in average blood pressure.
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Discussion
Summary of key findings
In this community-dwelling cohort of older people, MAP
measured over two decades was associated with structural brain
changes, most notably, greater white matter hyperintensities.
Compared with normotensive individuals, participants with
hypertension showed greater hyperintensities, in particularly in
deep rather than periventricular white matter. Those with poorly
controlled hypertension showed the greatest white matter hyper-
intensities. Given that both poorly controlled hypertension and
hypertension of greater duration were associated with more
adverse brain outcomes, our findings suggest a dose–response
relationship between elevated blood pressure during adulthood
and brain structure at older ages.
Our results are consistent with two previous studies that
found that the risk of severe white matter hyperintensities was
higher in those with high blood pressure taking antihypertensive
agents (equivalent to ‘poorly controlled hypertension’), compared
with those with normal blood pressure taking antihypertensive
medication (equivalent to ‘controlled hypertension’).37,38 Our
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Fig. 1 Age- and gender-adjusted association of hypertension status in 2012–2013 with visual magnetic resonance imaging (MRI)
outcomes (*P50.05).
Table 4 Longitudinal association of mean arterial pressurea across clinical examinations between 1985 and 2009 with magnetic
resonance imaging (MRI) brain measures in 2013
Visual measuresa Automated measuresa
ORb (95% CI) P b-value (s.e.) P
Global atrophy 0.8 (0.6–1.2) 0.3 8038.9 (10139.7) 0.4
Left hippocampus 1.2 (0.7–1.9) 0.5 70.003 (0.003) 0.3
Right hippocampus 1.7 (1.0–2.8) 0.03 70.002 (0.003) 0.6
White matter
Deep 1.3 (0.9–1.9) 0.2 N/A
Periventricular 1.0 (0.7–1.5) 0.9 N/A
Fazekas/total 1.2 (0.8–1.7) 0.4 0.2 (0.06) 0.002
a. Mean arterial pressure (MAP) = ((26mean DBP) +mean SBP)/3 where mean DBP and mean SBP are mean diastolic and systolic blood pressure across five clinical examinations
between 1985 and 2009, respectively.
b. Adjusted for age and gender.
c. Per 10 unit increment.
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Fig. 2 Age- and gender-adjusted association between mean
arterial pressure over 24 years and automated white matter
hyperintensity volume (95% confidence intervals shown with
dashed line).
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study adds to this evidence using data obtained from automated
as well as visual techniques for MRI analysis, and considering
hypertension history over a longer period: we found that differences
in systolic and diastolic blood pressure between normotensive,
untreated hypertensive, controlled hypertensive and poorly
controlled hypertensive participants were already evident 28 years
before the MRI brain scan. Although this could suggest that long-
term exposure may be a key determinant of hypertension-related
changes in the brain, our analysis of the longitudinal data
showed that this was possible to observe for total white matter
hyperintensities and right hippocampal atrophy only. The
association of hypertension with brain structure could represent
an underlying mechanism for the hypothesised vascular origins
of common mental illness in late life, including cognitive
impairment and depression. There is conflicting evidence to
support treatment of hypertension as a way of preventing the
symptoms of dementia and depression,39,40 and this is an area that
could usefully be explored in further studies.
We found a stronger association with deep white matter
regions than with periventricular regions. Some previous studies
also found that deep white matter and periventricular lesions
may be differentially influenced by vascular risk factors. For
example, there is an association between deep white matter
hyperintensities and hypertension,17 whereas periventricular white
matter hyperintensities are associated with a history of cerebro-
vascular disease.41 A possible explanation is that deep and
periventricular white matter lesions have different pathogenesis,
with the former attributable to small vessel disease (and therefore
with hypertension), and the latter being haemodynamically
determined, and linked to large vessel disease.34 Our findings,
which emphasise the associations of hypertension with deep white
matter, are in keeping with the hypothesis that deep white matter
pathological changes are mediated by microvascular change.42 In
principle, such pathology could also lead to global brain atrophy,43
however, we found no significant differences between groups for
global atrophy.
Strengths and limitations
The strength of our study includes the use of prospective data on
hypertension and antihypertensive treatment, collected six times
over 28 years. Together with this extensive blood pressure data,
we used high resolution (3 Tesla) MRI to acquire detailed data
on brain structure. Our use of visual and automated assessment
methods enables our findings to be translated into clinical
practice, while providing results with a high degree of confidence
and accuracy.
There were some discrepancies between results obtained in
relation to visual and automated measures. This may be because
these measures relate to similar, but not identical anatomical
correlates. For example, the visual measure of medial temporal
lobe atrophy is slightly different to the automated measure of
hippocampal volume; visual measures separated periventricular
and deep white matter hyperintensities, whereas automated
measures did not. A further issue is that despite high levels of
interrater reliability, visual assessments of MRI brain scans still
retain a degree of subjectivity, not present when using automated
measures. By their nature, visual assessments are performed ‘by
eye’ and therefore only detect major changes, whereas automated
measures have the potential to detect more subtle changes in brain
structure.
In this study, long-term exposure to hypertension was
modelled as the MAP based on the average measure of blood
pressure readings recorded five times between 1985 and 2009. This
method assesses long-term exposure to hypertension in a manner
that incorporates all available data, allowing it to be used as a
continuous variable in regression models with MRI variables as
outcomes. As this method is simple, it also provides direct
relevance to measures available within clinical practice. More
complex, multilevel modelling, such as area under the curve,
could have been used as an alternative, but these models would
have detracted from the clarity of the data and the ability to
transfer our findings to clinical practice. Given that the data-
collection phases in Whitehall II were approximately equally
spaced (every 5 years), the simple mean of these measures is likely
to correlate strongly with these alternative methods as a measure
of exposure to the risk factor.
Our study contains smaller numbers compared with some
previous cohorts, especially for the group with controlled
hypertension.14,22,37 Although the size of our sample was sufficient
to detect hypertension-related differences in white matter
hyperintensities, no significant differences were found for global
and hippocampal atrophy. There has been more controversy in
previous literature about the association between hypertension
and grey-matter atrophy, compared with white matter atrophy,
therefore it is possible that this association is weaker and our
sample underpowered to detect such differences. However, our
sample size is probably sufficient to suggest that exposure to
hypertension is unlikely to have a strong effect on grey matter
changes. All our participants were from an occupational cohort,
and have participated in the Whitehall II study for over 25 years,
a group likely to represent a potentially higher-functioning,
more health-conscious cohort than the general population.
Generalisability is further limited by the fact that the majority
of participants were men.
Clinical relevance
Our results support the hypothesis that there is an association
between hypertension and white matter brain changes, both
cross-sectionally and longitudinally. The worst brain structure
was found in those with poorly controlled hypertension, a group
of people with the longest history of high blood pressure, which
has become unresponsive, or is poorly responsive to treatment.
Randomised controlled trials are needed to determine the
potential benefits of targeting this group for enhanced secondary
prevention of vascular disease. In terms of clinical practice, this
group might benefit from focused education on the importance
of treatment and assistance with making lifestyle modifications
to reduce their blood pressure, as well as more aggressive
pharmacotherapy.
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Irmfried Eberl: psychiatry and the Third Reich
Ciaran Somers
Dr Irmfried Eberl, Austrian and member of the National Socialist German Workers (NAZI) party
was appointed in 1939 as head of the Brandenburg Psychiatry Facility, despite limited training
and experience in psychiatry. In 1940 he commenced coordination of mass killing of mentally
ill patients there as part of the T4 euthanasia programme: 9772 patients were killed at
Brandenburg and 8601 at Bernberg, another facility under his control.
Holding the rank of SS Obersturmfu¨hrer, Eberl was commissioned in 1942 with the preparation
of the Treblinka concentration camp for ethnic cleansing of Jews and other minorities, the only
physician to hold such a command under the Nazis. His enthusiasm to increase the throughput
of Treblinka ultimately resulted in his dismissal as commandant, as the disposal of the bodies
fell significantly behind, creating a cremation backlog. He was charged with war crimes in 1947
but hanged himself while awaiting trial.
Close to 300 000 patients with schizophrenia were either sterilised or killed in Nazi Germany. 0f
600–700 psychiatrists practising there at the time, it is unclear how many refused to participate
or protested. A few, including Hans Creutzfeldt, protested publicly.
The gas chamber as a method of mass killing originated in German psychiatric hospitals. Economic factors were the main reason
given by the Nazis – their propaganda campaign reported that maintaining one ‘life-unworthy retard’ in an asylum would support
40 poor families. Hitler in 1941 granted immunity from prosecution for medical staff who subjected their mentally ill patients to
euthanasia. Strict ‘criteria’ were laid down to qualify, including a diagnosis of schizophrenia and criminal insanity. The assessors
for the T4 programme included Werner Villinger, Friedrich Mauz and Friedrich Panse, all three subsequent presidents of the Society
of German Neurologists and Psychiatrists (GDNP) in the postwar years. Before they were killed many of the patients were used for
research, including Carl Schneider’s (professor of psychiatry at Heidelberg University) experiments on mentally ill children.
When the war ended a collective denial descended on German psychiatry. Professor Werner Heyde, medical director of the T4
programme, enjoyed a second career as a court-appointed medical expert in Schleswig-Holstein, under an assumed name. Many
in both the medical and legal professions were aware of his real identity. In 1945 Professor Gerhard Schmidt, former director of
the psychiatric clinic in Lu¨beck, gave a radio talk about the crimes committed against the mentally ill. For 20 years he was unable
to find a publisher for the manuscript on the topic, as many psychiatrists were afraid that publication of the details of these crimes
would prevent efforts to rebuild the profession.
Government legislation also reflected this denial. In 1965, the revised Federal Indemnification Law provided for the indemnification of
victims of Nazi crimes, but excluded those who had been forcibly sterilised as it was argued they had not been persecuted for
reasons of race. Some of the expert witnesses for the Bundestag’s Restitution Committee in the 1960s had themselves participated
in the forced sterilisations and killings during the Third Reich. Werner Villinger rejected the idea of compensation payments on the
grounds that they might cause the victims to develop ‘neurotic ailments’. The Nazi-enacted Law for the Prevention of Hereditary
Diseased Offspring was finally repealed in 2007. The Federal Indemnification Law remains unchanged, meaning that the mentally
ill have not been explicitly acknowledged as victims of the Nazi regime. In 2010 Professor Frank Schneider, president of the German
Association for Psychiatry and Psychotherapy (DGPPN), acknowledged that with just a few exceptions a large majority of
German psychiatrists took part in planning, implementing and creating scientific legitimacy for sterilisation and murder under the
Nazi regime. He apologised to the victims and their relatives for the pain and injustice they endured at the hands of German
psychiatrists during that period and for the subsequent silence, trivialisation and denial that had characterised psychiatry in postwar
Germany.
Schneider F. Psychiatry under National Socialism – Remembrance and Responsibility. DGPPN, 2010. Available at: https://www.dgppn.de/history/
psychiatry-under-national-socialism/speech-professor-schneider.html (accessed May 2014).
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